EXPO:NASDAQExponent, Inc. Analysis
Data as of 2026-09-05 - not real-time
$68.35
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Exponent, Inc. is priced at $68.35, and its moving averages give no clean directional read — the structure is neutral. It has gained 11.2% over the past 30 days. Momentum indicators put RSI at 50.3 (neutral) with MACD reading bearish. The recent range runs from support at $65.27 up to resistance at $71.92.
Multiples put this in fair territory: 30.7 times earnings against the sector's 28.5. Analyst price targets sit 22.9% above the current price. Revenue is growing at 12.0% on a 19.7% profit margin. The 1.76% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 25.9%, a beta of 0.47 and a maximum drawdown of 32.7%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
Multiples put this in fair territory: 30.7 times earnings against the sector's 28.5. Analyst price targets sit 22.9% above the current price. Revenue is growing at 12.0% on a 19.7% profit margin. The 1.76% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 25.9%, a beta of 0.47 and a maximum drawdown of 32.7%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.
Top Market Events
Exponent Inc EXPO delivered a strong Q2 2026 with net revenues up 12%, driven by AI integration into physical products...MENLO PARK, Calif., July 30, 2026 GLOBE NEWSWIRE -- Exponent, Inc. Nasdaq: EXPO today announced that its Board of...MENLO PARK, Calif., July 30, 2026 GLOBE NEWSWIRE -- Exponent, Inc. Nasdaq: EXPO today reported financial results for...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Trading above the 200-day average of 66.98
- MACD momentum is negative
- 30-day price change of +11.2%
Medium Term
1–3 yearsPositive
Model confidence: 4/10
Key Factors
- P/E of 30.7 versus sector average of 28.5
- Trading above the 200-day average of 66.98
- Analyst targets imply +22.9% versus the current price
Long Term
> 3 yearsPositive
Model confidence: 5/10
Key Factors
- P/E of 30.7 versus sector average of 28.5
- Analyst targets imply +22.9% versus the current price
- Profit margin of 19.7% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth12.00%
Profit Margin19.71%
P/E Ratio30.7
ROE31.20%
ROA11.29%
Debt/Equity27.97
P/B Ratio11.3
Op. Cash Flow$118.1M
Free Cash Flow$76.9M
Industry P/E28.5
Technical Analysis
TrendNeutral
RSI50.3
Support$65.27
Resistance$71.92
MA 20$69.28
MA 50$65.52
MA 200$66.98
MACDBearish
VolumeStable
Fear & Greed Index95.48
Valuation
Fair Value$33.53
Target Price$84.00
Upside/Downside22.90%
GradeFair
TypeGrowth
Dividend Yield1.76%
Risk Assessment
Beta0.47
Volatility25.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.